<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02492594</url>
  </required_header>
  <id_info>
    <org_study_id>VB MD-AN-007-3D</org_study_id>
    <nct_id>NCT02492594</nct_id>
  </id_info>
  <brief_title>Optimized Diagnostics for Improved Therapy Stratification in Invasive Fungal Infections</brief_title>
  <acronym>FUNGITECT</acronym>
  <official_title>Optimized Diagnostics for Improved Therapy Stratification in Invasive Fungal Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Anna Kinderkrebsforschung</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Anna Kinderkrebsforschung</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Invasive fungal infections (IFI) in immunocompromised patients pose a major challenge for
      diagnostics designed to permit timely onset of appropriate treatment. The aim of the current
      clinical-diagnostic studies, one in in pediatric and one in adult patients at high risk of
      IFI, is to test newly developed diagnostic approaches to invasive fungal infections in
      relation to established procedures. The studies will be performed in a prospective, blinded
      fashion, and represent a work package within the FUNGITECT grant supported by the European
      Commission. The studies will focus on analyses of blood-samples from patients with febrile
      neutropenia during treatment of acute leukemia or after hematopoietic stem cell
      transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Samples from immunosuppressed patients with febrile neutropenia will be taken:

        -  at the start of neutropenic fever

        -  after 24 hours

        -  after 48 hours

        -  before the start of antimycotic therapy, if pertinent

        -  at the end of antimycotic therapy, if pertinent

      The results ot analyses by a panfungal PCR screening assay developed at our institution
      (European patent No 1960536) and methods newly developed during the FUNGITECT project will be
      compared with conventional methods for fungal diagnostics such as HR (High Resolution)-CT,
      serological testing, histology and fungal culture. Additionally, genomic approaches will be
      employed to investigate host- and pathogen-related factors of susceptibility, pathogenicity
      and antimycotic resistance.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with fungal DNAmia (as indicator of fungal infection) detected by new methodologies described in the proposal</measure>
    <time_frame>until the end of antifungal treatment (up to 6 weeks after the onset of febrile neutropenia)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of individual fungal pathogens during febrile neutropenia in high risk patients</measure>
    <time_frame>until the end of antifungal treatment (up to 6 weeks after the onset of febrile neutropenia)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of fungal pathogens resistant to commonly used antifungal agents</measure>
    <time_frame>until the end of antifungal treatment (up to 6 weeks after the onset of febrile neutropenia)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of lethal fungal infections</measure>
    <time_frame>until the end of antifungal treatment (up to 6 weeks after the onset of febrile neutropenia)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Invasive Fungal Infections</condition>
  <arm_group>
    <arm_group_label>Pediatric patients with febrile neutropenia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Peripheral blood samples of up to 200 pediatric patients with severe immunosuppression and neutropenic fever will be analyzed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adult patients with febrile neutropenia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Peripheral blood samples of up to 200 adult patients with severe immunosuppression and neutropenic fever will be analyzed</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Peripheral blood sampling</intervention_name>
    <description>Peripheral blood samples will be taken at 3-5 defined timepoints during febrile neutropenia, together with blood sampling for routine diagnostic purposes.</description>
    <arm_group_label>Pediatric patients with febrile neutropenia</arm_group_label>
    <arm_group_label>Adult patients with febrile neutropenia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Adult study:

          -  Patients between 18-90 years of age with high risk of invasive fungal infections
             (individuals with acute leukemia on chemotherapy/allogeneic stem cell transplant
             recipients),

          -  signed informed consent

        Pediatric study:

          -  patients between 0-18 years of age with high risk of invasive fungal infections
             (individuals with acute leukemia on chemotherapy/allogeneic stem cell transplant
             recipients),

          -  signed informed consent

        Exclusion criteria:

        Adult study:

          -  pregnancy,

          -  no signed informed consent

          -  Pediatric study no signed informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Lion, Prof MD PHD</last_name>
    <role>Study Director</role>
    <affiliation>St. Anna Kinderkrebsforschung</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Lion, Prof MD PHD</last_name>
    <phone>0043-1-40470</phone>
    <phone_ext>4890</phone_ext>
    <email>thomas.lion@ccri.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefan Czurda, PHD</last_name>
    <phone>0043-1-40470</phone>
    <phone_ext>4875</phone_ext>
    <email>stefan.czurda@ccri.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hanusch Krankenhaus</name>
      <address>
        <city>Vienna</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felix Keil, Prof MD</last_name>
      <email>felix.keil@wgkk.at</email>
    </contact>
    <contact_backup>
      <last_name>Elisabeth Koller, MD</last_name>
      <email>elisabeth.koller@wgkk.at</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>St. Anna Children's Hospital</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Peters, Prof MD PHD</last_name>
      <phone>+43-1-40470</phone>
      <phone_ext>3106</phone_ext>
      <email>christina.peters@stanna.at</email>
    </contact>
    <investigator>
      <last_name>Christina Peters, Prof MD PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Pediatric Hematology and Oncology Teaching Hospital Motol, 2nd Medical School, Charles University</name>
      <address>
        <city>Prague</city>
        <zip>150 06</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Petr Sedlacek, Prof MD PhD</last_name>
      <email>petr.sedlacek@fnmotol.cz</email>
    </contact>
    <investigator>
      <last_name>Petr Sedlacek, Prof MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czech Republic</country>
  </location_countries>
  <link>
    <url>http://www.kinderkrebsforschung.at/</url>
  </link>
  <results_reference>
    <citation>Landlinger C, Preuner S, Bašková L, van Grotel M, Hartwig NG, Dworzak M, Mann G, Attarbaschi A, Kager L, Peters C, Matthes-Martin S, Lawitschka A, van den Heuvel-Eibrink MM, Lion T. Diagnosis of invasive fungal infections by a real-time panfungal PCR assay in immunocompromised pediatric patients. Leukemia. 2010 Dec;24(12):2032-8. doi: 10.1038/leu.2010.209. Epub 2010 Sep 30.</citation>
    <PMID>20882044</PMID>
  </results_reference>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2015</study_first_submitted>
  <study_first_submitted_qc>July 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2015</study_first_posted>
  <last_update_submitted>July 3, 2015</last_update_submitted>
  <last_update_submitted_qc>July 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Invasive Fungal Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

